ECCO 12 - the European Cancer Conference

August 20, 2003

ECCO 12 - the European Cancer Conference
Sunday 21 September - Thursday 25 September 2003
Bella Center A/S, Center Boulevard, Copenhagen, Denmark


Join 10,000 international cancer experts at ECCO 12 - Europe's premier cancer conference: the only forum in Europe covering the entire spectrum of research, treatment and care for all types of tumours. An opportunity to hear the latest research findings and sit in on debates and discussions on controversies in cancer.

  • Registration free for all media providing bona fide press credentials
  • All sessions open to journalists
  • A fully equipped media centre with computers and free phone and internet facilities
  • Daily news briefings

    News briefing programme (subject to confirmation):

    Sunday 21 September 17.00hrs:
    • Join EU and FECS' representatives for a Round Table discussion on R and D challenges in cancer and the growing problem of unequal access to cancer care in Europe. Your chance to quiz the experts.
    Monday 22 September 13.00hrs:
    • Dr Michael Stratton: Cancer genes - a realistic target for drug development?
    • Dr Nicolaj Andreassen: Tailoring radiotherapy - new findings predict sensitivity to radiation damage
    • Prof. Richard Peto: Hormonal treatment in prostate & breast cancer - latest findings on increasing 10-year survival
    Tuesday 23 September 13.00hrs
    • Prof Anthony Howell: Update on ATAC [Arimidex, Tamoxifen Alone or in Combination] trial
    • Prof Peter Ravdin: First head-to-head paclixtaxel v docetaxel trial in breast cancer - world-first presentation of findings
    • Lynn Faulds-Wood & Kathy Redmond - launch of the European Cancer Patient Coalition (ECPC) - Europe's first patient advocacy group for all types of cancer
    Wednesday 24 September 13.00hrs
    • Prof Jens Overgaard: Shorter radiotherapy helps head and neck cancer patients (results from the DAHANCA trial)
    • Prof Bengt Glimelius: New insights into treating colorectal cancer
    • Prof Jaap Verweij: International trials - how they proved new treatment for rare cancer - but will this be possible in future?
    • Dr Patrick Therasse: Clinical trials in danger from EU legislation
    Thursday 25 September 09.30hrs
    • Prof Michel Coleman: Eurocare-3 - first results from long-awaited follow up study on cancer survival rates in different European countries
    To find full details of the programme:
    Visit the Federation of European Cancer Societies' web site:
    http://www.fecs.be/Conferences/ecco12/index.shtml

    To register now via the web go to:
    www.fecs.be/conferences/ecco12/media.shtml
    Or register on site from 09.00hrs Sunday 21 September 2003.

    Further information or need a registration form?
    For more help about media registration and the media programme or to request a form: please contact Margaret Willson at m.willson@mwcommunications.org.uk or tel. 44-153-677-2181
    -end-
    Please note: the details in this alert about the news briefings is provided for information only - to give advance notice to editors about the forthcoming ECCO programme. However, the information itself is embargoed until the time within the conference when these presentations are made.

    ECCO-the European CanCer Organisation

    Related Breast Cancer Articles from Brightsurf:

    Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
    The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

    Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
    New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

    Partial breast irradiation effective treatment option for low-risk breast cancer
    Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

    Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
    Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

    More clues revealed in link between normal breast changes and invasive breast cancer
    A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

    Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
    A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

    Computers equal radiologists in assessing breast density and associated breast cancer risk
    Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

    Blood test can effectively rule out breast cancer, regardless of breast density
    A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

    Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
    Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

    Young breast cancer patients undergoing breast conserving surgery see improved prognosis
    A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

    Read More: Breast Cancer News and Breast Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.